Akoya Historical Financial Ratios

AKYA Stock

USD 1.48 0.06 3.90%

Akoya Biosciences is presently reporting on over 102 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.002, PTB Ratio of 15.65 or Days Sales Outstanding of 74.33 will help investors to properly organize and evaluate Akoya Biosciences financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.

About Akoya Financial Ratios Analysis

Akoya BiosciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Akoya Biosciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Akoya financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Akoya Biosciences history.

Akoya Biosciences Financial Ratios Chart

At present, Akoya Biosciences' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Days Sales Outstanding is expected to grow to 74.33, whereas Price To Sales Ratio is forecasted to decline to 1.32.

Price To Sales Ratio Dividend Yield Days Sales Outstanding Ev To Sales

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Akoya Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Akoya Biosciences sales, a figure that is much harder to manipulate than other Akoya Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Akoya Biosciences dividend as a percentage of Akoya Biosciences stock price. Akoya Biosciences dividend yield is a measure of Akoya Biosciences stock productivity, which can be interpreted as interest rate earned on an Akoya Biosciences investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most ratios from Akoya Biosciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Akoya Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.At present, Akoya Biosciences' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Days Sales Outstanding is expected to grow to 74.33, whereas Price To Sales Ratio is forecasted to decline to 1.32.

	2024	2025 (projected)
Dividend Yield	0.002254	0.002004
Price To Sales Ratio	1.39	1.32

Dividend Yield Price To Sales Ratio

Akoya Biosciences fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		0.65	-0.64	0.78	-0.6	0.94	0.89	0.77	-0.64	1.0	0.86	0.96	0.97	0.9	-0.94	-0.69	0.5	-0.58	-0.87	0.08	-0.66	-0.71	-0.93	0.75	0.43	0.82
Dividend Yield	0.65		-0.45	0.33	-0.07	0.82	0.35	0.78	-0.45	0.64	0.3	0.72	0.69	0.35	-0.84	-0.26	0.7	-0.04	-0.51	-0.4	-0.8	-0.5	-0.55	0.36	0.43	0.9
Ptb Ratio	-0.64	-0.45		-0.92	0.65	-0.59	-0.48	-0.51	1.0	-0.64	-0.47	-0.58	-0.72	-0.6	0.65	0.76	-0.17	0.39	0.21	0.12	0.45	-0.06	0.35	-0.83	-0.94	-0.65
Days Sales Outstanding	0.78	0.33	-0.92		-0.83	0.63	0.76	0.43	-0.92	0.79	0.76	0.7	0.83	0.84	-0.7	-0.78	0.04	-0.66	-0.47	0.22	-0.39	-0.17	-0.59	0.84	0.76	0.59
Book Value Per Share	-0.6	-0.07	0.65	-0.83		-0.36	-0.74	-0.1	0.65	-0.63	-0.76	-0.42	-0.69	-0.77	0.5	0.41	0.24	0.94	0.51	-0.53	0.07	0.25	0.58	-0.46	-0.44	-0.27
Free Cash Flow Yield	0.94	0.82	-0.59	0.63	-0.36		0.71	0.9	-0.59	0.93	0.67	0.95	0.92	0.72	-0.97	-0.67	0.71	-0.32	-0.79	-0.19	-0.85	-0.7	-0.84	0.72	0.42	0.94
Operating Cash Flow Per Share	0.89	0.35	-0.48	0.76	-0.74	0.71		0.42	-0.48	0.9	1.0	0.84	0.87	0.99	-0.74	-0.51	0.12	-0.81	-0.89	0.51	-0.34	-0.7	-0.92	0.58	0.26	0.52
Capex To Depreciation	0.77	0.78	-0.51	0.43	-0.1	0.9	0.42		-0.51	0.75	0.35	0.76	0.71	0.43	-0.8	-0.64	0.92	-0.03	-0.55	-0.56	-0.78	-0.54	-0.61	0.68	0.41	0.86
Pb Ratio	-0.64	-0.45	1.0	-0.92	0.65	-0.59	-0.48	-0.51		-0.64	-0.47	-0.58	-0.72	-0.6	0.65	0.76	-0.17	0.39	0.21	0.12	0.45	-0.06	0.35	-0.83	-0.94	-0.65
Ev To Sales	1.0	0.64	-0.64	0.79	-0.63	0.93	0.9	0.75	-0.64		0.87	0.95	0.98	0.91	-0.94	-0.67	0.48	-0.62	-0.88	0.11	-0.65	-0.72	-0.94	0.74	0.43	0.81
Free Cash Flow Per Share	0.86	0.3	-0.47	0.76	-0.76	0.67	1.0	0.35	-0.47	0.87		0.81	0.84	0.99	-0.7	-0.49	0.04	-0.83	-0.86	0.56	-0.29	-0.66	-0.9	0.56	0.26	0.48
Roic	0.96	0.72	-0.58	0.7	-0.42	0.95	0.84	0.76	-0.58	0.95	0.81		0.92	0.85	-0.93	-0.65	0.51	-0.42	-0.82	0.05	-0.71	-0.69	-0.88	0.72	0.43	0.86
Inventory Turnover	0.97	0.69	-0.72	0.83	-0.69	0.92	0.87	0.71	-0.72	0.98	0.84	0.92		0.88	-0.96	-0.65	0.41	-0.64	-0.83	0.11	-0.69	-0.65	-0.9	0.72	0.51	0.85
Net Income Per Share	0.9	0.35	-0.6	0.84	-0.77	0.72	0.99	0.43	-0.6	0.91	0.99	0.85	0.88		-0.75	-0.6	0.09	-0.79	-0.81	0.47	-0.34	-0.59	-0.87	0.67	0.4	0.55
Days Of Inventory On Hand	-0.94	-0.84	0.65	-0.7	0.5	-0.97	-0.74	-0.8	0.65	-0.94	-0.7	-0.93	-0.96	-0.75		0.59	-0.57	0.44	0.79	0.08	0.83	0.66	0.85	-0.66	-0.48	-0.95
Payables Turnover	-0.69	-0.26	0.76	-0.78	0.41	-0.67	-0.51	-0.64	0.76	-0.67	-0.49	-0.65	-0.65	-0.6	0.59		-0.39	0.2	0.34	0.19	0.57	0.15	0.45	-0.98	-0.59	-0.62
Capex To Revenue	0.5	0.7	-0.17	0.04	0.24	0.71	0.12	0.92	-0.17	0.48	0.04	0.51	0.41	0.09	-0.57	-0.39		0.26	-0.38	-0.74	-0.7	-0.5	-0.39	0.4	0.13	0.68
Cash Per Share	-0.58	-0.04	0.39	-0.66	0.94	-0.32	-0.81	-0.03	0.39	-0.62	-0.83	-0.42	-0.64	-0.79	0.44	0.2	0.26		0.65	-0.69	-0.04	0.44	0.68	-0.25	-0.18	-0.16
Pocfratio	-0.87	-0.51	0.21	-0.47	0.51	-0.79	-0.89	-0.55	0.21	-0.88	-0.86	-0.82	-0.83	-0.81	0.79	0.34	-0.38	0.65		-0.32	0.52	0.95	0.99	-0.38	0.04	-0.61
Interest Coverage	0.08	-0.4	0.12	0.22	-0.53	-0.19	0.51	-0.56	0.12	0.11	0.56	0.05	0.11	0.47	0.08	0.19	-0.74	-0.69	-0.32		0.41	-0.19	-0.29	-0.18	-0.23	-0.33
Payout Ratio	-0.66	-0.8	0.45	-0.39	0.07	-0.85	-0.34	-0.78	0.45	-0.65	-0.29	-0.71	-0.69	-0.34	0.83	0.57	-0.7	-0.04	0.52	0.41		0.51	0.56	-0.56	-0.29	-0.93
Capex To Operating Cash Flow	-0.71	-0.5	-0.06	-0.17	0.25	-0.7	-0.7	-0.54	-0.06	-0.72	-0.66	-0.69	-0.65	-0.59	0.66	0.15	-0.5	0.44	0.95	-0.19	0.51		0.89	-0.17	0.29	-0.52
Pfcf Ratio	-0.93	-0.55	0.35	-0.59	0.58	-0.84	-0.92	-0.61	0.35	-0.94	-0.9	-0.88	-0.9	-0.87	0.85	0.45	-0.39	0.68	0.99	-0.29	0.56	0.89		-0.49	-0.11	-0.67
Days Payables Outstanding	0.75	0.36	-0.83	0.84	-0.46	0.72	0.58	0.68	-0.83	0.74	0.56	0.72	0.72	0.67	-0.66	-0.98	0.4	-0.25	-0.38	-0.18	-0.56	-0.17	-0.49		0.69	0.67
Income Quality	0.43	0.43	-0.94	0.76	-0.44	0.42	0.26	0.41	-0.94	0.43	0.26	0.43	0.51	0.4	-0.48	-0.59	0.13	-0.18	0.04	-0.23	-0.29	0.29	-0.11	0.69		0.53
Roe	0.82	0.9	-0.65	0.59	-0.27	0.94	0.52	0.86	-0.65	0.81	0.48	0.86	0.85	0.55	-0.95	-0.62	0.68	-0.16	-0.61	-0.33	-0.93	-0.52	-0.67	0.67	0.53

Click cells to compare fundamentals

Akoya Biosciences Account Relationship Matchups

Akoya Biosciences fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	17.49	10.43	4.83	2.24	1.39	1.32
Ptb Ratio	39.97	4.72	6.17	4.03	14.9	15.65
Days Sales Outstanding	55.64	62.77	47.44	64.19	61.58	74.33
Free Cash Flow Yield	(0.0137)	(0.0718)	(0.17)	(0.25)	(0.41)	(0.39)
Operating Cash Flow Per Share	(0.18)	(0.96)	(1.42)	(1.15)	(0.89)	(0.94)
Capex To Depreciation	0.86	1.06	1.03	0.41	0.32	0.3
Pb Ratio	39.97	4.72	6.17	4.03	14.9	15.65
Ev To Sales	17.91	8.97	4.85	2.27	1.34	1.27
Free Cash Flow Per Share	(0.27)	(1.1)	(1.61)	(1.23)	(0.94)	(0.99)
Roic	(0.19)	(0.23)	(0.45)	(0.39)	(0.47)	(0.5)
Inventory Turnover	3.88	2.3	2.17	2.26	1.39	1.32
Net Income Per Share	(0.45)	(1.15)	(1.87)	(1.43)	(1.12)	(1.18)
Days Of Inventory On Hand	94.1	158.95	168.02	161.8	262.68	275.82
Payables Turnover	3.26	2.19	2.96	3.42	3.86	2.38
Capex To Revenue	0.0776	0.0928	0.0983	0.0378	0.0301	0.0286
Cash Per Share	0.46	3.02	2.15	1.87	0.71	1.18
Pocfratio	(108.46)	(15.89)	(6.75)	(4.26)	(2.57)	(2.69)
Interest Coverage	(4.22)	(11.95)	(14.54)	(6.58)	(4.48)	(4.7)
Pfcf Ratio	(73.21)	(13.92)	(5.94)	(3.97)	(2.43)	(2.55)
Days Payables Outstanding	112.01	166.37	123.27	106.58	94.6	141.44
Roe	(0.9)	(0.35)	(1.21)	(1.18)	(7.29)	(6.93)
Ev To Operating Cash Flow	(111.09)	(13.65)	(6.78)	(4.31)	(2.48)	(2.6)
Pe Ratio	(44.43)	(13.34)	(5.11)	(3.42)	(2.04)	(2.15)
Return On Tangible Assets	(0.46)	(0.28)	(0.51)	(0.44)	(0.6)	(0.63)
Ev To Free Cash Flow	(74.99)	(11.96)	(5.96)	(4.02)	(2.35)	(2.47)
Earnings Yield	(0.0225)	(0.0749)	(0.2)	(0.29)	(0.49)	(0.46)
Intangibles To Total Assets	0.53	0.21	0.22	0.2	0.26	0.34
Net Debt To E B I T D A	(1.78)	2.29	(0.0264)	(0.0566)	0.1	0.11
Current Ratio	1.67	5.09	3.03	3.45	2.61	2.37
Tangible Book Value Per Share	(0.6)	2.19	0.54	0.41	(0.51)	(0.48)
Receivables Turnover	6.56	5.82	7.69	5.69	5.93	4.66
Debt To Equity	1.88	0.27	1.29	1.59	1.05	0.7
Capex Per Share	0.0888	0.14	0.19	0.0822	0.0497	0.0472
Graham Net Net	(0.95)	1.47	(0.57)	(0.49)	(1.21)	(1.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock:

How To Invest In Akoya

Details

Is Akoya Stock a good investment?

Details

What is Akoya Biosciences' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.12)

Revenue Per Share

1.653

Quarterly Revenue Growth

(0.19)

Return On Assets

(0.17)

Return On Equity

(1.80)

The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Akoya Historical Financial Ratios

About Akoya Financial Ratios Analysis

Akoya Biosciences Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Ev To Sales

Akoya Biosciences fundamentals Correlations

Akoya Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Akoya Biosciences fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 0.99	Operating Cash Flow Per Share
Net Income Per Share	+ 0.99	Free Cash Flow Per Share
Pfcf Ratio	+ 0.99	Pocfratio

Days Payables Outstanding	- 0.98	Payables Turnover
Days Of Inventory On Hand	- 0.97	Free Cash Flow Yield
Days Of Inventory On Hand	- 0.96	Inventory Turnover
Roe	- 0.95	Days Of Inventory On Hand
Pfcf Ratio	- 0.94	Ev To Sales
Days Of Inventory On Hand	- 0.94	Ev To Sales